1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B8E9A30D4A4ACF7065257F400044A92F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/rems-excellence-models-trends-supporting-rems-program-success
18
19
2018.212.90.230
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Quality, Compliance and Regulatory Deployment

REMS Excellence: Models & Trends in Supporting REMS Program Success

ID: POP-270


Features:

13 Info Graphics

15 Data Graphics

180+ Metrics


Pages: 38


Published: 2016


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Considering the stringent regulatory requirements in the health care industry, it is important for biopharmaceutical companies to develop innovative Risk evaluation and mitigation strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.


Given the complexity of balancing regulatory requirements and commercial objectives, Best Practices, LLC undertook benchmarking research to examine how leading life sciences and medical device companies develop and execute successful REMS plans for newly-approved drugs in the U.S. market.

In particular, the study provides insights around the structure and responsibilities of REMS teams, use of internal and external resources to support REMS programs, physician/ distributor compliance on ETASU, current challenges in REMS communication plans and innovative REMS approaches for new products.


Industries Profiled:
Pharmaceutical; Consulting; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbvie; Oxon Epidemiology; Arthur F. Morelli and Associates; Baxter BioScience; Bayer; Cadila Pharmaceuticals; Eisai; Gilead Sciences; Hospira; Lilly; MedicinesOracle; Novartis; Pfizer; Reliance Life Sciences; Sanofi; Scientific Advantage; UCB Pharma


Study Snapshot

Best Practices, LLC engaged 20 leaders from 17 leading biopharmaceutical and medical device companies through a benchmarking survey. More than 50% of participants are at the level of director/ senior director and around 20% of participants are CEO/president.

Key Findings

Pharmacovigilance & Medical Affairs Functions Lead REMS: According to the study, REMS programs are mainly led by Pharmacovigilance (at 42% of benchmark companies) and Medical Affairs (26%). Additional support functions such as regulatory affairs, and sub-functions such as clinical and commercial also support overall REMS activities at some organizations. Market Research serves very limited role in REMS at any participating companies.

“Internal Database and Past Internal REMS Plans Serve as Most Used Internal Resource: Most companies use past internal REMS programs, for drugs in different therapeutic area (65%) or same therapeutic area (53%). Almost half of the companies also refer internal research repositories/database.


Table of Contents

Executive Summary, pgs. 3-10
Research Overview, pg. 4
Participating Companies, pg. 5
Abbreviations used, pg. 6
Key Recommendations, pg. 7
Key Findings & Insights , pgs. 8-10
Benchmark Class Profile, pgs. 11-12
REMS Program: Structure & Responsibilities, pgs. 13-17
Industry Experience In Developing & Deploying Successful REMS Plans, pgs. 18-22
REMS Approaches For New Products, pgs. 23-26
Leveraging Resources For REMS Efficiency & Excellence , pgs. 27-31
REMS Communication Plans: Current Challenges, pgs. 32-36
About Best Practices, LLC, pgs. 37-38

List of Charts & Exhibits

Functional group leading REMS program at benchmarked organizations
Level of lead job title
Groups holding primary leadership role for listed REMS plan components
Groups supporting listed REMS plan components
Number of products for which REMS plan has been implemented at benchmarked companies
REMS plan experience of participating organizations
Communication activities managed by REMS organization
Effectiveness of ETASU activities managed by REMS organization
Stage of new product development process at which REMS planning begins
Strategies adopted for inducing physician and/or distributor compliance for drugs requiring an ETASU REMS plan
Percentage of research associated with REMS plans conducted internally versus outsourced to external vendors
Resources used by REMS function to leverage external approved REMS plans (data) from other companies
Resources used by REMS function to leverage internal research completed by brand teams and franchise units
Collaboration with other organizations
Balancing REMS communication strategy and messaging to not only inform physicians of treatment risk but to also instill greater confidence in treatment
Balancing risk (from the clinical perspective) vs. commercial impact (from the marketing perspective) in the context of REMS program deployment for new products
Integration of REMS support functions within benchmarked companies
Effective policies for integrating REMS support functions